×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Chorea Market

ID: MRFR/HC/51938-HCR
200 Pages
Rahul Gotadki
October 2025

UK Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care)-Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Chorea Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

UK Chorea Market Summary

As per MRFR analysis, the UK chorea market Size was estimated at 36.0 USD Million in 2024. The UK chorea market is projected to grow from 38.33 USD Million in 2025 to 71.66 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.46% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The UK chorea market is experiencing a transformative phase driven by advancements in treatment and rising awareness.

  • Rising awareness and education about chorea disorders are enhancing patient engagement and care.
  • Advancements in treatment options are expanding the therapeutic landscape for chorea management.
  • Technological integration in care is streamlining patient monitoring and improving outcomes.
  • The increasing prevalence of chorea disorders and government initiatives are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 36.0 (USD Million)
2035 Market Size 71.66 (USD Million)

Major Players

Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi (FR), Pfizer Inc (US), Eli Lilly and Company (US), AstraZeneca PLC (GB)

UK Chorea Market Trends

The chorea market in the UK is currently experiencing notable developments, driven by a combination of increasing awareness and advancements in treatment options. The prevalence of chorea, often associated with conditions such as Huntington's disease, has led to a growing demand for effective therapies and supportive care. Healthcare providers are increasingly focusing on personalized treatment plans, which may enhance patient outcomes. Furthermore, the integration of innovative technologies in monitoring and managing symptoms appears to be gaining traction, potentially improving the quality of life for affected individuals. In addition, the regulatory landscape is evolving, with authorities emphasizing the need for rigorous clinical trials and safety assessments. This shift may encourage pharmaceutical companies to invest in research and development, fostering a more competitive environment. As the chorea market continues to expand, collaboration between stakeholders, including healthcare professionals, researchers, and patient advocacy groups, seems essential for addressing the unique challenges faced by individuals with chorea. Overall, the future of this market appears promising, with ongoing efforts to enhance treatment accessibility and efficacy.

Rising Awareness and Education

There is an increasing focus on raising awareness about chorea and its associated conditions. Educational initiatives aimed at healthcare professionals and the public are likely to improve early diagnosis and treatment options. This trend may lead to better management of symptoms and enhanced patient support.

Advancements in Treatment Options

The chorea market is witnessing significant advancements in therapeutic options. New medications and treatment modalities are being developed, which may offer improved efficacy and safety profiles. This trend could potentially transform the management of chorea, providing patients with more effective solutions.

Technological Integration in Care

The integration of technology in the management of chorea is becoming increasingly prevalent. Digital health tools and telemedicine are being utilized to monitor symptoms and provide remote support. This trend may enhance patient engagement and facilitate timely interventions, ultimately improving health outcomes.

UK Chorea Market Drivers

Advancements in Genetic Research

Recent advancements in genetic research have the potential to revolutionize the chorea market. The identification of specific genetic markers associated with chorea disorders, such as Huntington's disease, has opened new avenues for targeted therapies. In the UK, ongoing studies are exploring gene therapy as a viable treatment option, which could significantly alter the management of chorea. The potential for personalized medicine, tailored to individual genetic profiles, may enhance treatment efficacy and patient outcomes. As these research initiatives progress, they are likely to attract investment and interest from pharmaceutical companies, further driving growth in the chorea market.

Government Initiatives and Funding

Government initiatives aimed at improving healthcare access and funding for neurological disorders play a crucial role in shaping the chorea market. The UK government has allocated substantial resources to research and development in the field of neurology, with funding reaching approximately £1.5 billion annually. Such investments are likely to enhance the understanding of chorea and its underlying causes, leading to the development of innovative treatment options. Additionally, public health campaigns aimed at raising awareness about chorea disorders may encourage early diagnosis and intervention, ultimately benefiting the chorea market. These initiatives not only support patients but also foster collaboration among researchers, healthcare providers, and pharmaceutical companies.

Emerging Pharmaceutical Innovations

The chorea market is witnessing a surge in pharmaceutical innovations aimed at addressing the unmet needs of patients. Recent developments in drug formulations and delivery systems are enhancing the efficacy of existing treatments while minimizing side effects. The UK pharmaceutical sector has seen investments exceeding £2 billion in research and development for neurological disorders, including chorea. These innovations are likely to lead to the introduction of novel therapies that could transform treatment paradigms. As new products enter the market, competition among pharmaceutical companies may intensify, ultimately benefiting patients through improved access to effective treatments in the chorea market.

Increasing Prevalence of Chorea Disorders

The rising incidence of chorea disorders in the UK is a notable driver for the chorea market. Recent estimates suggest that the prevalence of Huntington's disease, a primary cause of chorea, affects approximately 12.1 individuals per 100,000 in the UK. This growing patient population necessitates enhanced healthcare services and treatment options, thereby stimulating market growth. As awareness of these disorders increases, more individuals seek diagnosis and treatment, further propelling the demand for therapeutic interventions. The chorea market is likely to expand as healthcare providers adapt to the needs of this demographic, ensuring that effective management strategies are in place to address the complexities associated with chorea disorders.

Rising Demand for Supportive Care Services

The increasing recognition of the need for supportive care services for individuals with chorea disorders is a significant driver in the chorea market. As the complexities of managing chorea become more apparent, families and caregivers are seeking comprehensive support systems. This includes access to physiotherapy, occupational therapy, and psychological support, which are essential for improving the quality of life for patients. The UK healthcare system is gradually adapting to these needs, with an estimated £500 million allocated to enhance supportive care services. This shift not only benefits patients but also creates opportunities for businesses specializing in care solutions, thereby contributing to the overall growth of the chorea market.

Market Segment Insights

By Type: Huntington's Disease (Largest) vs. Drug-induced Chorea (Fastest-Growing)

In the UK chorea market, Huntington's disease represents the largest segment, commanding a significant market share due to its prevalence and the ongoing demand for specialized treatments. This segment benefits from well-established clinical guidelines and a continued focus on research and development, which ensures sustained interest and investment. On the other hand, drug-induced chorea is emerging as the fastest-growing segment. This trend can be attributed to the increasing awareness of the condition arising from various medications, as well as a rising incidence of related side effects. Healthcare providers are increasingly focused on recognizing this form of chorea, leading to more diagnoses and a growing market for targeted therapies.

Huntington's Disease (Dominant) vs. Drug-induced Chorea (Emerging)

Huntington's disease is currently the dominant segment in the UK chorea market. It is characterized by a well-defined patient population and established treatment protocols, driving consistent demand. The segment's strength lies in its visibility within clinical settings and significant support from patient advocacy groups. Conversely, drug-induced chorea is considered an emerging segment, marked by its rapid growth due to rising recognition among healthcare professionals. This form of chorea is often underdiagnosed, and its increasing acknowledgment is leading to the development of specific treatment options. As awareness continues to grow, this segment is likely to see a notable increase in market share, fueled by the need for better management of medication-induced effects.

By Treatment: Medical Care (Largest) vs. Surgical Care (Fastest-Growing)

In the UK chorea market, the treatment segment is primarily bifurcated into medical and surgical care, with medical care holding the largest market share. This segment is favored due to its comprehensive approach to managing chorea symptoms, leveraging effective pharmacological therapies. In contrast, surgical care, while currently smaller, is gaining traction due to advancements in surgical techniques and heightened patient awareness, positioning it as a significant area of growth. The growth trends in this segment are driven by a combination of technological advancements in medical therapies and a shift towards minimally invasive surgical procedures. Patients are increasingly opting for surgical interventions as a viable option, stimulated by positive clinical outcomes and endorsements from healthcare professionals. The emphasis on personalized treatment plans further propels the demand for both segments, indicating a dynamic evolution in the treatment landscape of the market.

Medical Care: Dominant vs. Surgical Care: Emerging

Medical care is characterized by the use of pharmacotherapies, which provide symptomatic relief and are often the first line of treatment for chorea. Its dominance in the UK chorea market is attributed to established treatment protocols, robust clinical data supporting efficacy, and widespread acceptance among healthcare providers. Conversely, surgical care represents an emerging segment, focusing on advanced surgical techniques like deep brain stimulation. As awareness of these techniques increases and outcomes become more favorable, surgical care is anticipated to capture more market share. Both segments cater to the growing demand for effective chorea management and are influenced by emerging research and patient preferences.

By Distribution Channel: Pharmacies (Largest) vs. Clinics (Fastest-Growing)

In the distribution channel segment of the UK chorea market, pharmacies hold the largest market share, providing convenience and accessibility to patients, which solidifies their position as a primary source for treatments. Other distribution channels, such as hospitals and diagnostic centers, also contribute significantly but on a smaller scale, with hospitals focusing on comprehensive care and diagnostic centers offering specialized services. Clinics, while currently a smaller segment, are rapidly expanding due to an increase in outpatient services and a rising preference for localized care. The growth of the distribution channel segment is primarily driven by the evolving healthcare landscape in the UK chorea market. Factors influencing this growth include the increasing demand for accessible healthcare services, an aging population requiring more medical attention, and advancements in technology that allow for more effective distribution methods. Furthermore, the rise of telemedicine and home healthcare solutions is fostering relationships with pharmacies and clinics, enabling them to capture a larger share of the market by offering essential services and medications directly to patients' homes.

Pharmacies: Dominant vs. Clinics: Emerging

Pharmacies play a dominant role in the UK chorea market, widely recognized for their accessibility and essential services, providing a range of medications and health consultations. Their established infrastructure allows for efficient distribution of treatments, making them the go-to option for consumers. In contrast, clinics are emerging as significant players, particularly due to the rising trend of outpatient care. They are increasingly recognized for their personalized services, focusing on specific health needs, which positions them well in the current market dynamics. As consumers seek convenient and immediate healthcare solutions, both pharmacies and clinics are adapting to meet these evolving requirements through enhanced service offerings and patient engagement strategies.

By Symptoms: Involuntary Muscle Movements (Largest) vs. Milkmaid's Grip (Fastest-Growing)

In the UK chorea market, the segment values exhibit a diverse distribution with involuntary muscle movements being the dominant symptom, capturing the largest market share. This symptom significantly impacts patient quality of life and is frequently observed in chorea patients. Milkmaid's grip, while currently smaller in market share, is rapidly gaining traction due to increased awareness and clinical recognition, making it a focused area for research and treatment. Growth trends in this segment are driven primarily by advancements in medical technology and therapies that address symptoms more effectively. The rising incidence of chorea due to various neurological conditions has further fueled the demand for targeted symptomatic treatments. Additionally, the growing understanding of symptom management and the importance of early diagnosis are expected to propel the market forward, particularly for emerging symptoms like milkmaid's grip.

Involuntary Muscle Movements (Dominant) vs. Milkmaid's Grip (Emerging)

Involuntary muscle movements are characterized by uncontrolled, spontaneous movements that can severely hinder daily activities and overall patient wellbeing, marking it as the dominant value in the UK chorea market. This category encompasses a range of symptoms, including jerking and twitching, which are often the most recognizable signs of chorea. On the other hand, milkmaid's grip represents an emerging segment that describes a specific type of hand movement mimicking the action of milking, seen in a subset of chorea patients. While still developing its market presence, the recognition of milkmaid's grip as a significant symptom is growing, driven by increased research and a push for better therapeutic interventions tailored to this unique manifestation.

By End-Users: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the UK chorea market, the end-user segment is primarily led by hospitals, which account for the largest share due to their extensive resources and capabilities for handling complex cases. Clinics follow as a substantial portion of the market, leveraging their accessibility and convenience for patients needing specialized care for chorea. In contrast, ambulatory surgical centers and other types of healthcare facilities make up a smaller fraction of the total market share, but they play a significant role in delivering focused care. The growth trends within the end-user segment reflect a growing inclination towards outpatient services, particularly in clinics and ambulatory surgical centers. Factors such as the rising prevalence of chorea and increased awareness about treatment options are driving this segment's expansion. Furthermore, the shift towards less invasive procedures and decentralized healthcare settings is propelling clinics to emerge as the fastest-growing segment, as they offer efficient and timely interventions which align with patient preferences.

Hospitals: Dominant vs. Clinics: Emerging

Hospitals occupy a dominant position in the UK chorea market, characterized by their comprehensive infrastructure and a wide array of services. They are equipped to manage acute cases of chorea, providing multidisciplinary approaches that incorporate neurology, psychiatry, and rehabilitation services. Conversely, clinics are an emerging segment, known for their nimbleness and patient-centric care. They offer specialized services that cater to the needs of patients with chorea, making them a more attractive option for less complex cases. The rise of telemedicine and increased investment in outpatient facilities further contribute to the growth of clinics, making them a competitive player in the landscape, while hospitals continue to serve as the backbone of serious health interventions. Their coexistence highlights a balanced healthcare ecosystem addressing diverse patient needs.

Get more detailed insights about UK Chorea Market
Request Free Sample

Key Players and Competitive Insights

The chorea market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), and AbbVie Inc (US) are actively shaping the market through their distinct operational focuses. Teva (IL) emphasizes a strategy centered on cost-effective generics and specialty medications, which positions it favorably in a market that increasingly values affordability alongside efficacy. Bristol-Myers Squibb (US) appears to be leveraging its robust pipeline of innovative therapies, particularly in neurology, to capture market share, while AbbVie (US) is focusing on strategic acquisitions to enhance its portfolio in neurodegenerative diseases, thereby reinforcing its competitive stance.

The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing, which are crucial in a moderately fragmented market. This competitive structure allows for a diverse range of products and services, yet the influence of major players remains pronounced. Their collective strategies not only enhance operational efficiencies but also contribute to a more resilient market capable of responding to evolving patient needs and regulatory demands.

In October 2025, Teva Pharmaceutical Industries Ltd (IL) announced a partnership with a leading UK research institution to develop a novel treatment for chorea, which underscores its commitment to innovation and collaboration in addressing unmet medical needs. This strategic move is likely to enhance Teva's research capabilities and accelerate the development of new therapies, potentially positioning the company as a leader in the chorea treatment landscape.

In September 2025, Bristol-Myers Squibb Company (US) launched a new clinical trial for a promising drug aimed at chorea management, reflecting its focus on advancing therapeutic options. This initiative not only demonstrates the company's dedication to addressing the complexities of chorea but also signals its intent to solidify its presence in the neurology sector, potentially leading to significant market advantages.

In August 2025, AbbVie Inc (US) completed the acquisition of a biotech firm specializing in gene therapies for neurodegenerative disorders, which may enhance its capabilities in the chorea market. This acquisition is strategically important as it allows AbbVie to diversify its product offerings and leverage cutting-edge technology, thereby positioning itself competitively in a rapidly evolving landscape.

As of November 2025, the chorea market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances among key players are shaping the competitive environment, fostering innovation and enhancing operational efficiencies. Looking ahead, the competitive differentiation in this market is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains, suggesting a transformative shift in how companies engage with the market.

Key Companies in the UK Chorea Market market include

Industry Developments

The UK Chorea Market has seen notable developments in recent months, particularly concerning key players such as Teva Pharmaceutical Industries, Eli Lilly and Company, Amgen, and Pfizer. In September 2023, AstraZeneca announced its collaboration with Otsuka Pharmaceutical to enhance research and development efforts in chorea therapies, marking a significant step towards addressing unmet needs in the patient population. 

Moreover, growth has been observed in the market valuation of companies like Roche and Lundbeck, which are investing heavily in innovative treatments for chorea, further driving market interest. Over the past couple of years, UK regulatory bodies have streamlined approval processes for chorea medications, leading to increased accessibility and potentially expanding patient populations. 

Meanwhile, in July 2023, AbbVie and GSK were involved in discussions regarding potential mergers aimed at strengthening their platforms in neurological disorders, which could reshape the landscape of the chorea market, although specific agreements are still under negotiation. The competitive environment remains dynamic as companies focus on advancing therapies to provide effective solutions for patients suffering from chorea-related conditions, thus impacting overall market growth positively.

Future Outlook

UK Chorea Market Future Outlook

The Chorea Market is projected to grow at a 6.46% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

  • Development of telehealth platforms for remote patient monitoring.
  • Investment in personalized medicine targeting chorea symptoms.
  • Expansion of clinical trial networks to accelerate drug approvals.

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovative treatment solutions.

Market Segmentation

UK Chorea Market Type Outlook

  • Huntington's disease
  • Rheumatic (Sydenham's Chorea)
  • Drug-induced Chorea

UK Chorea Market Symptoms Outlook

  • Involuntary muscle movements
  • Milkmaid's grip
  • Speech problems
  • Seizures

UK Chorea Market End-Users Outlook

  • Clinics
  • Hospitals
  • Ambulatory surgical centers
  • Others

UK Chorea Market Treatment Outlook

  • Medical care
  • Surgical care

UK Chorea Market Distribution Channel Outlook

  • Hospitals
  • Clinics
  • Diagnostic centers
  • Drug stores
  • Pharmacies
  • Others

Report Scope

MARKET SIZE 2024 36.0(USD Million)
MARKET SIZE 2025 38.33(USD Million)
MARKET SIZE 2035 71.66(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.46% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi (FR), Pfizer Inc (US), Eli Lilly and Company (US), AstraZeneca PLC (GB)
Segments Covered Type, Treatment, Distribution Channel, Symptoms, End-Users
Key Market Opportunities Advancements in gene therapy and personalized medicine present new avenues in the chorea market.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the chorea market.
Countries Covered UK

Leave a Comment

FAQs

What is the expected market size of the UK Chorea Market in 2024?

The UK Chorea Market is expected to be valued at 30.0 USD Million in 2024.

What will the market size of the UK Chorea Market be by 2035?

By 2035, the UK Chorea Market is projected to reach a valuation of 92.5 USD Million.

What is the CAGR for the UK Chorea Market from 2025 to 2035?

The overall market is expected to grow at a CAGR of 10.779% from 2025 to 2035.

What is the market size of hospitals in the UK Chorea Market for 2024?

The market size for hospitals in the UK Chorea Market is valued at 10.5 USD Million in 2024.

How much is the clinics segment valued in the UK Chorea Market in 2035?

The clinics segment is projected to be valued at 23.0 USD Million in 2035.

Which companies are the major players in the UK Chorea Market?

Key players include Teva Pharmaceutical Industries, Eli Lilly and Company, and Amgen among others.

What is the market value for diagnostic centers in the UK Chorea Market in 2024?

In 2024, diagnostic centers in the UK Chorea Market are valued at 4.0 USD Million.

What challenges are expected to be faced in the UK Chorea Market?

Challenges may include regulatory hurdles and competition among key players.

What will be the market size of drug stores in the UK Chorea Market by 2035?

The drug stores segment is anticipated to reach a value of 15.0 USD Million by 2035.

How is the pharmacies segment of the UK Chorea Market expected to grow by 2035?

The pharmacies segment is expected to grow to 10.0 USD Million by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓